ISSN-E: 2617-9563

Determine the Children's Quality of Life Who Suffer From Major Beta Thalassemia

ISSN-E: 2617-9563

Abstract:
Investing in children and teenagers pays off in the long run. Taking care of children and teenagers is, therefore, an investment in creating the best possible social environment for the future. It is estimated that between 10 and 15 percent of today's kids are living with a chronic illness. One of the chronic diseases listed is thalassemia major. An absence of globin chains in the haemoglobin molecule causes the symptoms of thalassemia, a genetic blood illness, including severe and persistent anaemia, failure to thrive, hepatosplenomegaly, and bone deformities. These people are particularly vulnerable to the negative consequences that painful, prolonged, and repetitive treatment regimens can have on their physical health, mental health, and quality of life. The study's overarching goal was to ascertain the quality of life of children with major beta thalassemia, and its results indicated that these children had a higher-than-average quality of life in terms of their physical, mental, and environmental health, but a lower-than-average quality of life in terms of their relationships with other people. Research examined how cranial and facial deformities affect mental health. In order to improve these patients' quality of life, organisations with the power to do so are asked to pay more attention to a wide range of factors. In addition to consulting experts, patients and their loved ones need to be educated on the issue.
Key words : Children's Quality , Beta Thalassemia , Life Who Suffer From Major Beta Thalassemia.

الملخص:
الاستثمار في الأطفال والمراهقين يؤتي ثماره على المدى الطويل. لذلك ، فإن رعاية الأطفال والمراهقين هي استثمار في خلق أفضل بيئة اجتماعية ممكنة للمستقبل. تشير التقديرات إلى أن ما بين 10 و 15 في المائة من أطفال اليوم يعانون من مرض مزمن. أحد الأمراض المزمنة المذكورة هو مرض الثلاسيميا الكبرى. يؤدي غياب سلاسل الغلوبين في جزيء الهيموجلوبين إلى ظهور أعراض مرض الثلاسيميا ، وهو مرض وراثي في الدم ، بما في ذلك فقر الدم الشديد والمستمر ، وفشل النمو ، وتضخم الكبد والطحال ، وتشوهات العظام. هؤلاء الأشخاص معرضون بشكل خاص للعواقب السلبية التي يمكن أن تحدثها أنظمة العلاج المؤلمة والممتدة والمتكررة على صحتهم البدنية وصحتهم العقلية ونوعية حياتهم. كان الهدف الشامل للدراسة هو التأكد من جودة حياة الأطفال المصابين بالثلاسيميا بيتا الرئيسية ، وأشارت نتائجها إلى أن هؤلاء الأطفال يتمتعون بنوعية حياة أعلى من المتوسط من حيث صحتهم الجسدية والعقلية والبيئية ، ولكن أقل. - جودة الحياة المتوسطة من حيث علاقتها بالآخرين. فحص البحث كيف تؤثر تشوهات الجمجمة والوجه على الصحة العقلية. من أجل تحسين نوعية حياة هؤلاء المرضى ، يُطلب من المنظمات التي لديها القدرة على القيام بذلك إيلاء المزيد من الاهتمام لمجموعة واسعة من العوامل. بالإضافة إلى الخبراء الاستشاريين ، يحتاج المرضى وأحبائهم إلى التثقيف بشأن هذه المشكلة.
الكلمات المفتاحية: جودة الأطفال ، بيتا ثلاسيميا ، حياة من يعاني من الثلاسيميا بيتا.

Introduction:

Spending time on kids and teens pays dividends down the road. Hence, any effort made to care for children and teenagers is a step towards establishing the future's most crucial framework and optimal social setting. Anywhere between 10 and 15 percent of today's children are said to have a chronic health condition. These include thalassemia major, which is one of the chronic disorders mentioned. Thalassemia is a genetic blood ailment characterized by severe and persistent anemia, failure to thrive and hepatosplenomegaly, and bone abnormalities, all of which are brought on by a lack of globin chains in the hemoglobin molecule. In these individuals, unpleasant, protracted, and repetitive treatment regimens can have severe and considerable effects on their general health, psychological health, and quality of life. Patients experience a wide range of stresses, including shame, hopelessness, anxiety, concerns about their futures in terms of education and career, difficulties with their treatments, concerns about their welfare, cultural, and family obligations, and more. Almost twenty thousand Iranians of all ages have thalassemia major. Adolescents make up almost 10 percent of the population with chronic disorders like thalassemia. Patients with thalassemia often struggle emotionally and socially due to a number of factors, including the long course of their illness, the high cost of care, the severity of their symptoms, and the knowledge that they may die young (Jha,,2014).

Over 300 million people are carriers of thalassemia, making it the most prevalent genetic anaemia worldwide. The East Mediterranean, Southeast Asia, and India are hotspots for this hemoglobinopathy. In the northern and southern areas of Iran, thalassemia is also a big health problem. Around 10% of the world's thalassemia population lives in Guilan, making it one of the regions hardest hit by the disease. Although thalassemia major is lethal if not treated, the prognosis and survival rate of these patients has greatly improved due to developments in diagnostic tools and treatment strategies over the past decade (Charoenboon et al ,2016).

The quality of life these patients have in terms of their health is a major matter that should be addressed alongside the issue of increasing their chances of survival from this and other chronic conditions. Because of its long-term nature, thalassemia poses a wide spectrum of complex medical and emotional difficulties. Because of these difficulties, not only do patients' physical, emotional, and social functioning suffer, but so does their quality of life and their relationship with their loved ones. HRQOL is expected to be a key outcome and the allocation of health care resources appear mandatory for chronic disorders like thalassemia, for which a cure is not possible and lifelong therapy is required (Tartaglione, 2021).

They also have a lot of issues participating in educational and social activities with their peers. states Sixty-seven percent of thalassemic patients have anxiety, 62 percent struggle with emotions, particularly depression, and 49 percent have trouble communicating. In comparison to the general population, thalassemic patients were more likely to have a high physical activity index (47.9%, P 0.0001), poor mental health (64.9%, P 0.0001), and a suspected mental disease diagnosis (20.5%) than the general population (14.6%, P 0.0001). Based on the findings, it was clear that thalassemic patients needed the assistance of trained mental professionals. They worry a lot about their sickness, their treatment, and their health. Chronic symptoms of this disease, such as psychological exhaustion, increase the need for psychosocial therapies for the elderly. There is a strong link between these patients' quality of life and their performance, particularly in terms of their academic achievements, according to studies. Programs aiming to give psychological support and effective communication between the patient, school authorities, family, and physician are essential to improve the physical quality of life of these individuals. Patients with thalassemia who are in critical condition, including those using deferoxamine, require specialised medical treatment. In order to effectively plan for the prevention, diagnosis, and timely treatment of issues in various areas of these patients' lives, it is crucial to develop social and health policies. Hence, a better quality of life for these children and their parents cannot be offered until all parts of the disease are addressed. So, assessing these patients' quality of life allows for a more nuanced comprehension of their individual requirements and the use of more targeted care and treatment strategies (Liaska,2016).

Results from the many studies conducted on the quality of life of this population have varied widely based on factors such as location, access to healthcare, and the strength of social and family networks. Nonetheless, advancements in health care delivery and the introduction of novel treatment approaches have contributed to a rise in the average lifespan of these individuals. Sadly, there is a lack of research into how thalassemia major affects the lives of children. The researchers set out to assess how children with thalassemia major fare in terms of their health-related quality of life (Carsote et al,2022).

A significant prevalence of thalassemia major patients and carriers has been documented in the Middle East and North Africa, making beta ()-thalassemia a major public health issue in these areas. Consanguineous marriage plays a role in this phenomenon (Sharma et al ,2017).
Patients with thalassemia major are subjected to intensive treatment beginning in infancy. This treatment consists of repeated blood transfusions and iron chelating therapy. In light of recent developments in the treatment of this condition, the average lifespan of a patient diagnosed now is significantly higher than it was in the past. However, the patient's QoL is negatively impacted due to the aforementioned difficulties in areas like mental health, physical health, social and educational functioning as a result of things like frequent blood transfusions, daily use of iron chelators, cardiac and hepatic problems, and splenectomy (Demosthenous et al ,2019).
Patients with thalassemia major have had their QoL evaluated, despite current research showing the value of enhanced QoL in treating chronic diseases and reducing their symptoms. Government agencies caring for people with this illness should be well-versed on its physical and mental effects in order to improve their patients' quality of life (Finianos et al,2018).

Epidemiology:

Countries near the north coast of Africa and South America, as well as those around the Mediterranean, have a higher prevalence of beta-thalassemia than those in Central Asia, the Middle East, India, Southern China, or the Far East. Cyprus (14%), Sardinia (10.3%), and Southeast Asia have all been reported to have the highest carrier frequency. Thalassemia has spread to nearly every country due to migration and intermarriage between different ethnic groups. A significant percentage of the world's population (1.5% or 80–90 million people) are carriers for beta Thalassemia. Unfortunately, there is a paucity of reliable data on carrier rates in many populations, particularly in regions of the world that are now experiencing or are likely to experience a high level of impact. Birth incidence of beta thalassemia homozygotes is 11,316 per year in India, while the overall carrier frequency of beta thalassemia is 4.05%, according to research by Madan et al. There are an estimated 3% beta thalassemia carriers in Bangladesh, according to a research by the World Health Organization. Every year, between 5,000 and 9,000 infants are born in Pakistan with beta thalassemia, and the country's estimated carrier rate is 5 to 7 percent, making for 9.8 million carriers overall. While there doesn't appear to be any publicly available information about the prevalence of beta thalassemia in Nepal, unpublished hospital records from Tribhuwan University Teaching Hospital indicate that it is more common among members of the tharu community (Jaing et al,2021).

Clinical description:

Major thalassemia Those who are homozygous for the beta-thalassemia gene are at risk for developing either thalassemia major or thalassemia intermedia. Those born with thalassemia major need regular blood transfusions to survive, and they typically seek medical attention within the first two years of life. Those who present later are considered to have thalassemia intermedia and do not require transfusion (Helmi et al,2017).
Thalassemia major causes babies to lose weight and look sickly. Hepato splenomegaly can lead to abdominal enlargement, difficulty eating, diarrhoea, irritability, frequent fevers, and other symptoms. Growth and development are normal until about age 10 or 11 if a regular transfusion programme is undertaken to keep the haemoglobin concentration at or above 9.5 to 10.5 g/dl. If affected individuals do not comply with chelation therapy, they run the danger of developing severe issues associated to post transfusion iron overload after the age of 10-11 years. Those who have been transfused adequately and given the right chelation may live for a long time after they reach 30. Childhood iron excess can have negative effects on development and sexual maturation. Later iron overload problems include heart disease (dilated myocardiopathy or infrequently arrythmias), liver disease (fibrosis and cirrhosis), and endocrine gland dysfunction (diabetes mellitus, hypogonadism and insufficiency of the parathyroid, thyroid, pituitary, and, less commonly, adrenal glands). The most significant and potentially fatal complication of iron overload in beta thalassemia is myocardial dysfunction due to transfusional siderosis. According to statistics, patients with beta thalassemia major have a 71% increased risk of dying from cardiac problems (Koohi et al,2019).
Untreated or inadequately transfused patients typically exhibit growth retardation, paleness, jaundice, dark skin pigmentation, weakness, genu valgum, splenomegaly, leg ulcers, the formation of tumours due to extramedullary hematopoiesis, and skeletal abnormalities due to an enlarged bone marrow. Deformities in the long bones of the legs and the usual craniofacial modifications (a bossed skull, prominent malar eminence, depressed bridge of the nose, a tendency towards a mongoloid slant of the eye, and hypertrophy of the maxillae, which tends to expose the upper

teeth) are also present. Without regular transfusions, most people don't make it to their third decade (Ahmadpanah et al ,2019).

Red cell distribution width (RDW) increases while haemoglobin concentration, RBCs, hematocrit, MCV, MCH, and MCHC all decrease. Hemoglobin levels are typically between 3 and 7 g/dl, with MCV between 50 and 60 fl oz and MCH between 12 and 18 pg. Visible anisocytosis, poikilocytosis (including fragmented and teardrop poikilocytes), hypochromia, and microcytosis are present in the blood film. Target cells, Pappenheimer bodies, and basophilic stippling have been observed. Defective hemoglobinization and dyserythropoietic characteristics are present in the circulating nucleated red cells. Anemia, neutropenia, and thrombocytopenia all worsen in children with large splenomegaly due to hypersplenism. Although absolute reticulocyte counts tend to rise following splenectomy, they are often quite low in the general population. When the spleen is no longer there, the body shows the classic symptoms of hyposplenism, including Howell-Jolly bodies, target cells, lymphocytosis, thrombocytosis, and large platelets. A large number of nucleated red cells and conspicuous Pappenheimer bodies characterise this condition. Aspirate of bone marrow reveals extreme erythroid proliferation. Nuclear lobulation and fragmentation, basophilic stippling, poor hemoglobinization, and the presence of alpha chain precipitates are all signs of severe dyserythropoiesis. Pseudo-Gaucher cells and macrophages that actively phagocytose are both noticeable. The amount of iron in your body is boosted (Khan et al ,2021).

Beta-thalassemia intermedia:

Thalassemia intermedia is characterised by a delayed onset of symptoms than thalassemia major, milder anaemia, and the absence or seldom need for transfusion. Very ill patients typically come between the ages of 2 and 6; these kids can survive without regular blood transfusions, but their growth and development are stunted. Other patients, however, have no symptoms until adulthood and have only mild anaemia as a result. Bone marrow often resorts to compensatory mechanisms, such as hypertrophy of erythroid marrow and the possibility of extramedullary erythropoiesis, to deal with chronic anaemia. The disease's aftereffects include skeletal and facial abnormalities, osteoporosis with pathologic fractures, and erythropoietic mass formation in organs such the spleen, liver, lymph nodes, chest, and spine. The spleen's enlargement is a side effect of its primary function, which is to remove dead and damaged RBCs from the circulation. Compression of the spinal cord, leading to paralysis, and intrathoracic masses are two examples of neurological complications that can result from extramedullary erythropoiesis. Gallstones are more prevalent in people with thalassemia intermedia due to inefficient erythropoiesis and peripheral hemolysis. Compared to those with thalassemia major, those with thalassemia intermedia are more likely to suffer from thrombosis if they have had their spleen removed, and they are also more likely to develop leg ulcers. DVT, PTE, PE, and other similar conditions are examples of thromboembolic events (Adly & Ismail,2018).

Iron excess due to increased intestinal iron absorption is a risk for those with thalassemia intermedia, however hypogonadism, hypothyroidism, and diabetes are uncommon. Pregnancies that occur naturally are possible and may be healthy for women. However, those who have never or just moderately transfused blood are at danger of acquiring hemolytic alloantibodies and erythrocyte autoantibodies if they need blood transfusions during pregnancy. There have been reports of intrauterine growth retardation despite a healthy transfusion schedule. Whereas systolic left ventricular function is often retained, thalassemia intermedia patients can experience cardiac complications due to a high-output condition and pulmonary hypertension. Patients with this condition have been described as having pseudoxanthoma elasticum, a disorder of the connective tissue that manifests itself in the arteries through the degeneration of the elastic lamina of the artery wall and the subsequent accumulation of calcium (Vichinsky,2016).

Beta-thalassemia associated with other Hb anomalies:

Hemoglobin levels of 9–10 g/dL are optimal for growth and development, minimising bone abnormalities and hepatosplenomegaly caused by extramedullary hematopoiesis. Thalassemia is frequently accompanied with growth retardation and endocrinopathies, most notably hypogonadism. Most of the time, this is because of iron overload or persistent anaemia. When there is still endocrine deficiency, hormone replacement therapy is recommended. The infertility caused by hypogonadotropic hypogonadism is treatable, however, with the help of hormone replacement therapy for male patients. Few female patients have achieved pregnancy, either naturally (after appropriate chelation therapy) or with the help of assisted reproductive technologies. Osteoporosis and osteopenia are major causes of disability in the elderly. Chelation, lifestyle modifications (increasing calcium intake and physical exercise, and refraining from smoking), hormone therapy, and vitamin D therapy are all part of the management of bone disease (Asadov et al,2018).

Once other causes of elevated consumption, like hemolytic responses, have been ruled out, splenectomy should be considered if the annual red cell need is more than 180-200 ml/ Kg. Death and illness from thalassemia are typically brought on by an excess of iron in the body. Visceral organs (particularly the heart, liver, and endocrine glands) can accumulate iron, which leads to tissue damage and, eventually, organ malfunction. The sequential combination administration of deferiprone and deferoxamine is an exciting new method to chelation therapy (Bayati et al,2021). Although hematopoietic stem cell transplantation is now the only method of curing thalassemia, it has been severely constrained by factors such as its high cost and a lack of accessible HLA-matched, related donors. The intensity of iron accumulation is correlated with pretransplantation clinical abnormalities, such as hepatomegaly, liver fibrosis, and a lack of a chelation history. An HLA-identical sibling stem cell transplant has a disease-free survival rate of approximately 90% in patients lacking the aforementioned risk factors. A successful transplant eliminates the need for transfusions and, in most cases, chelation therapy (Casu et al ,2018).
A successful cure is possible with cord blood donation from a related donor, and the risk of GVHD is low. To stimulate foetal haemoglobin synthesis, pharmaceuticals are used such as 5-azacytidine, hydroxyurea, and a number of butyrate derivatives. The use of antioxidants, gene treatments, and molecular therapies to rectify the damage produced by the thalassemia mutation are also being studied (Li et al ,2018).

Prognosis:

The outlook for those with thalassemia mild is rather positive. It has been shown that there is an elevated risk of cholelithiasis The risk of cardiac complications is lower in patients with thalassemia intermedia because they often do not experience severe hemosiderosis. Patients in this subset may have a lower chance of survival due to pulmonary hypertension, thromboembolic consequences, severe sepsis after splenectomy, and the emergence of hepatocarcinoma. Without intervention, patients with thalassemia major typically pass away before they turn five years old. Regular transfusions and the development of iron chelators have allowed some people to live into their second decade (Schmidt et al,2018).
There are about 10,000 homozygous patients with thalassemia in developed regions like the United States and Europe, and the number of new cases has been steadily reducing due to efficient preventative strategies. Longer life expectancy and a higher quality of life are the results of the widespread availability of high-caliber medical care in these nations. In contrast, thalassemia treatment looks very different in developing nations, when services like universal access to safe transfusion and chelation are lacking. This results in the early deaths of many thalassemia patients in developing countries. Acceptable care programmes, such as safe blood transfusion and supporting therapy like chelation, need to be put in place. Prenatal diagnosis should be more widely available, and enhanced education and screening should be implemented as part of a standardised procedure for preventing thalassemia in these nations(Chauhan et al,2022).

Previse study:

According to Afifi & Almoqaid (2020),that every member of the family is affected emotionally, mentally, and physically when a kid receives a cancer diagnosis. An estimated 200,000 children and adolescents are diagnosed with cancer each year, with the vast majority residing in poor and middle-income nations where the mortality rate is disproportionately high. The purpose of this research is to compare and contrast health-related quality of life in children with various chronic illnesses. Children and their parents will be compared in terms of how each group assesses their own quality of life in this research. The relationships between quality of life and disease severity, duration, and the presence of additional co-morbidities will also be investigated. The Pediatric Quality of Life Inventory (PedsQL 4.0 generic core scale) was used in a prospective, analytical, correlational study design to evaluate the quality of life of 110 children: 50 children with cancer, 30 children with thalassemia, and 30 children receiving hemodialysis. Both children and their parents were questioned by the researchers. Among of the three groups of children, those with Thalassemia scored the lowest and had the worst quality of life. Surprisingly, children receiving dialysis had a lower quality of life than children with cancer. Nonetheless, there was a significant gap between the child's and parent's responses to scale questions. There was a statistically significant correlation between family characteristics such size, income, and parental education with the quality of life all children experienced. Our findings show that a significant proportion of the children enrolled in this study had a low health-related quality of life. The results show how important it is for local medical facilities to focus more on the quality of life of children with chronic diseases.
The purpose of this study is to identify the unique personal, mental, and social challenges that thalassemic individuals experience. It was a multi-center cross-sectional study. Location and Timeframe Research was conducted in the

Fatimid Foundation's centres in Karachi, Lahore, and Quetta from October 2009 to October 2010. One hundred and one thalassemia major transfusion-dependent participants were given an indigenously constructed Quality of Life (QoL) questionnaire based on the SF-36 questionnaire. Descriptive statistics for the variables were calculated using SPSS version 15. In this study, participants ranged in age from 6 to 21, with a mean age of 10.5. Only a minority of patients (less than a third) reported an improvement in their health over the previous year. As a result of their illness, 45% of patients reported feeling isolated. Surprisingly, the parents of 35 kids (35.6% of the total) sometimes restricted their children's playtime due to illness. Twenty-eight (27.7%) reported trouble interacting with peers their own age. Seventy-one percent (70.3%) of the patients expressed concern about their professional and personal futures, while seventy percent (69.3%) of the patients agreed that their friends and teachers took special care of them. Patients with thalassemic conditions reported a drastic decline in their quality of life. They are at a high risk for early-life psychological trauma due to their physical disabilities, social strains, financial constraints, and difficulties in school and the workplace. All of this makes it more difficult for them to mature into responsible, self-sufficient adults (Siddiqui & Sajid,2014)

According to Hamdy & Salemd (2021), this article was to use the short-form-36-questionnaire (SF-36) to measure patients with beta ()-thalassemia major's quality of life (QoL) and identify characteristics related to QoL. Patients with -thalassemia major who visited the haematology outpatient clinic at Cairo University Hospital were included in a cross-sectional study that employed the consecutive sampling method. The time period of data collection was from October 2016 to March 2017. Patients younger than 17 years old had their QoL evaluated. Overall, 112 patients were enrolled in the research during the course of its duration. Participants' mean ages were 18.32 1.33 years. Most of the patients that were included received at least one blood transfusion every month (93.63 percent). As a whole, SF-36 test takers had an average of 44.907.54. Patients' "general health perception" QoL domain was the worst affected, with a mean score of (add the value of the score here), while their "vitality" domain was the best. The mean score on the "vitality" category was substantially greater in males than in females ($p = 0.05$), but no other QoL domains were significantly different between the sexes. Patients' quality of life was favourably connected with their age at disease onset and with the time since their first blood transfusion. Results showed that people with thalassemia major have a lower quality of life. All thalassemia patients should have their quality of life (QoL) evaluated so that appropriate interventions can be designed and carried out to improve the damaged areas.

Similar to other chronic diseases, advances in thalassemia major therapy have increased patients' life expectancy and, by extension, the quality of life they might expect to enjoy. In order to get a better idea of how these patients in Guilan province are faring in terms of their health, this study was carried out. Thirty-one children with -thalassemia major were questioned in Guilan, northern Iran, between January and March 2016 for a cross-sectional study. The provincial health system and its outlying clinics, blood bank organizations, public and private hospitals, and clinics were mined for information. The PedsQL questionnaire was used to evaluate the subjects' health-related quality of life. All patients and their parents filled out the questionnaire at the beginning of treatment. In some cases, we utilised the T test, whereas in others, we used the Chi-square test. The majority of the 31 kids were female (58.1%). The children's summary score averaged 74.920.1. Scores on measures of physical, emotional, social, school, and psychosocial functioning were 70.6-24, 73.3-22.9, 85.9-21, 74.1-21.5, and 77.7-19.7, respectively. Not one of the kids needed to have their spleen removed. In this analysis, there was no correlation between quality of life and sex, serum ferritin, or haemoglobin levels. These individuals had passable QOL, but their HRQOL ratings were lower than the norm for the healthy population. It's clear that more community and family involvement is required to improve these kids' lives(Jafari-Shakib et al ,2016).

Understanding the elements that affect thalassemia patients' quality of life is crucial for developing effective clinical programmes, providing enough social support, and enhancing treatment outcomes. The researchers at the Center for Special Diseases at the valiasr hospital in Birjand set out to assess the quality of life of the young patients they treat for thalassemia major. Forty thalassemia major children older than seven participated in this cross-sectional descriptive-analytical investigation. A demographic questionnaire and the World Health Organization Quality of Life questionnaire (WHOQOL- Bref) standard questionnaire with 26 items were used to gather information about the quality of life of thalassemia patients. The data was analysed in SPSS using a combination of descriptive statistics (mean, standard deviation, and frequency) and an inferential statistic (t-test). The average results indicated a quality-of-life score of 70.379.88, a score of 253.06 for physical health, a score of 18.123.22 for mental health, a score of 21.34.43 for the home environment, and a score of 5.951.58 for sociability. Neither education nor age seemed to have any bearing on life satisfaction. There was a statistically significant (P0.0001) correlation between social connections and educational attainment. The results showed that the patient had an above-average quality of life in terms of their physical health, psychological health, and environmental health. However, the results also suggested that appropriate programmes be put in place to help these children on all fronts, from the medical to the social and emotional, as well as to better their relationship with the Center for Special Diseases (Kaheni et al,2013).

Results:

The effects of beta-thalassemia on youngsters are catastrophic and last a lifetime. Self-management of disease in addition to treatment plans to improve quality of life (QOL) is necessary for children with chronic diseases like thalassemia, which may boost compliance and, in turn, improve the health of these children.

Whereas the largest proportion of the children in the study reported mediocre or low quality of life in terms of their emotional functioning, the smallest proportion reported the same for their social functioning. In contrast to the findings of Baraz et al. (2016), who compared the quality of life of children with beta-thalassemia major to that of their healthy peers, we found that the children in our study scored significantly higher on the social aspects of quality of life while reporting significantly lower scores on mental health.

In terms of physical health, mental health, and ecological well-being, the participants reported above-average quality of life. Yet, quality of life was below par in terms of social connections. The limited quantity of goods in this dimension may contribute to the low quality of life in this area. The results of this study are consistent with those from a previous study of thalassemia patients and their families, which found a mean physical health score of 3.43, a mean psychological health score of 3.4, a mean environmental health score of 3.55, and a mean social relationship score of 2.6 (means were divided by the number of items in each dimension). Patients with thalassemia major on the southern coast of the Caspian Sea reported a high quality of life in the area of physical health, consistent with the results of the present study, but a low quality of life in the area of mental health, as measured by the shortened version of the SF-36 questionnaire.

The treatment of beta-thalassemia major relies on blood transfusions and chelation therapy. When blood is transfused early and regularly, severe anaemia and its associated complications decrease and life expectancy rises. The majority of people in the current study group who agreed to get a blood transfusion reported having a poor quality of life. This finding may be viewed in light of the fact that low haemoglobin levels are linked to a wide range of health issues, including lethargy, weakness, and impaired cognitive function. Children can contract life-threatening diseases such hepatitis C virus, human brucellosis virus, human immunodeficiency virus, malaria, syphilis, and human t-cell leukaemia virus (HTLV) from receiving donated blood. This study's findings were consistent with those of Thavorncharoensap et al. (2010), who found that transfusion recipients had a lower health-related quality of life than the general population. This finding may be explained by the fact that study participants in both studies had haemoglobin levels below the minimum threshold three months prior to the health-related quality of life estimation. Blood transfusions were found to have a negative effect on children's quality of life.

Quality of life improvements in this study can be attributed to greater and more effective cooperation of families in caring for these patients, as well as increased help from the Center for Special Diseases in this region. Age was examined as a potential mediator of quality of life, but no such association was found in this study. Observed no statistically significant link between the ages of their patients and their quality of life. However, Thavorncharoensap et al. discovered a significant (P0.05) relationship between age and quality of life. No significant link was found between patients' occupations and their quality of life in this investigation. The P-value for this association was lower than 0.05, indicating statistical significance. In addition, this study examined the link between educational attainment and quality of life, and it discovered that higher levels of education (0.03) were substantially connected with stronger social relationships (P= 0.0001). It has been found (P 0.05) that one's level of education correlates positively with one's satisfaction with life. The next factor that was examined was the association between clinical complications and quality of life, although this was also found to be inconsequential. The relationship between quality of life and clinical problems was shown to be statistically significant (P 0.05) in the study by Shaligram et al. Also, Thabvorncharoensap et al. found a substantial relationship between the seriousness of clinical problems and the patients' quality of life. It is possible that the small sample size contributed to the lack of a meaningful association between craniofacial alterations and quality of life in this study.

Medication class was another factor examined in the study, however it did not show a statistically significant relationship to overall satisfaction with life. Thavorncharoensap et al. identified a statistically significant (P 0.05) inverse association between iron chelation therapy and their outcomes. In this study, we looked at how often people take their medications each week and how that correlated with their quality of life, and we discovered no statistically significant relationship. Regular pharmaceutical use, as demonstrated has a negative impact on children's overall quality of life, particularly in the area of their interpersonal relationships. Like the study of Tahmasebi et al., the current research revealed no evidence of a link between splenectomy and QoL. The relationship between splenectomy and QoL was found to be weak in a research by Dahlui et al. (P=0.058). Unforeseen occurrences affecting patients' responses during interviews and questionnaires were a limitation of the study. Travel tiredness, weakness, and lack of energy, as well as a lack of patience to answer questions, could also be cited as reasons for patients' unwillingness to openly voice their ideas or participate with researchers.

Conclusion

Findings showed that the patient's quality of life was above average in terms of physical, psychological, and environmental health, but below average in terms of social interactions. The impact of craniofacial alterations on well-being was studied. Organizations that can make a difference in these patients' lives are urged to provide more attention to many elements of their lives in order to raise the bar for these individuals' quality of life. It is also important to utilise professionals and raise awareness among patients and their loved ones.

Reference :

Afifi, T., Elessi, K., Baraka, O., Omar, M., Ahmad, I., Al-Attar, H., ... & Almoqaid, A. (2020). Assessment of Quality of life Among Children with Cancer, Children Undergoing Hemodialysis and Children with Thalassemia: A Comparative Study.

Siddiqui, S. H., Ishtiaq, R., Sajid, F., & Sajid, R. (2014). Quality of life in patients with thalassemia major in a developing country. *JCPSP: Journal of the College of Physicians and Surgeons--Pakistan*, *24*(7), 477.

Hamdy, M., Draz, I. H., El Sayed, I. T., Ayyad, A. A. F., & Salemd, M. R. (2021). Assessment of Quality of Life among Beta-Thalassemia Major Patients Attending the Hematology Outpatient Clinics at Cairo University Hospital. *Open Access Macedonian Journal of Medical Sciences*, *9*(E), 156-160.

Jafari-Shakib, A., Davoudi-Kiakalaye, A., Pour-Fathollah, A. A., Jafari-Shakib, R., & Mohtasham-Amiri, Z. (2016). Health-related quality of life in β thalassemia major children in north of Iran. *Iranian Journal of Blood and Cancer*, *8*(4), 108-111.

Kaheni, S., Yaghobian, M., Sharefzadah, G. H., Vahidi, A., Ghorbani, H., & Abderahemi, A. (2013). Quality of life in children with β-thalassemia major at center for special diseases. *Iranian journal of pediatric hematology and oncology*, *3*(3), 108.

Baraz, S., Miladinia, M., & Mosavinouri, E. (2016). A comparison of quality of life between adolescences with beta thalassemia major and their healthy peers. *International Journal of Pediatrics*, *4*(1), 1195-1204.

Charoenboon, C., Jatavan, P., Traisrisilp, K., & Tongsong, T. (2016). Pregnancy outcomes among women with beta-thalassemia trait. *Archives of gynecology and obstetrics*, *293*, 771-774.

Thavorncharoensap, M., Torcharus, K., Nuchprayoon, I., Riewpaiboon, A., Indaratna, K., & Ubol, B. O. (2010). Factors affecting health-related quality of life in Thai children with thalassemia. *BMC Hematology*, *10*, 1-10.

Casu, C., Presti, V. L., Oikonomidou, P. R., Melchiori, L., Abdulmalik, O., Ramos, P., & Rivella, S. (2018). Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major. *Haematologica*, *103*(2), e46.

Vichinsky, E. (2016). Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. *Current medical research and opinion*, *32*(1), 191-204.

Asadov, C., Alimirzoeva, Z., Mammadova, T., Aliyeva, G., Gafarova, S., & Mammadov, J. (2018). β-Thalassemia intermedia: a comprehensive overview and novel approaches. *International journal of hematology*, *108*(1), 5-21.

Shaligram, D., Girimaji, S. C., & Chaturvedi, S. K. (2007). Psychological problems and quality of life in children with thalassemia. *The Indian Journal of Pediatrics*, *74*, 727-730.

Khan, A. M., Al-Sulaiti, A. M., Younes, S., Yassin, M., & Zayed, H. (2021). The spectrum of beta-thalassemia mutations in the 22 Arab countries: a systematic review. *Expert Review of Hematology*, *14*(1), 109-122.

Koohi, F., Kazemi, T., & Miri-Moghaddam, E. (2019). Cardiac complications and iron overload in beta thalassemia major patients—a systematic review and meta-analysis. *Annals of hematology*, *98*, 1323-1331.

Helmi, N., Bashir, M., Shireen, A., & Ahmed, I. M. (2017). Thalassemia review: features, dental considerations and management. *Electronic physician*, *9*(3), 4003.

Jaing, T. H., Chang, T. Y., Chen, S. H., Lin, C. W., Wen, Y. C., & Chiu, C. C. (2021). Molecular genetics of β-thalassemia: A narrative review. *Medicine*, *100*(45).

Jha, R., & Jha, S. (2014). Beta thalassemia-a review. *Journal of pathology of Nepal*, *4*(8), 663-671.

Liaska, A., Petrou, P., Georgakopoulos, C. D., Diamanti, R., Papaconstantinou, D., Kanakis, M. G., & Georgalas, I. (2016). β-Thalassemia and ocular implications: a systematic review. *BMC ophthalmology*, *16*(1), 1-13.

Demosthenous, C., Vlachaki, E., Apostolou, C., Eleftheriou, P., Kotsiafti, A., Vetsiou, E., ... & Sarafidis, P. (2019). Beta-thalassemia: renal complications and mechanisms: a narrative review. *Hematology*, *24*(1), 426-438.

Dahlui, M., Hishamshah, M. I., Rahman, A. J. A., & Aljunid, S. M. (2009). Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment. *Singapore medical journal*, *50*(8), 794.

Tartaglione, I., Carfora, R., Brotto, D., Barillari, M. R., Costa, G., Perrotta, S., & Manara, R. (2021). Hearing loss in beta-thalassemia: Systematic review. *Journal of Clinical Medicine*, *11*(1), 102.

Sharma, D. C., Arya, A., Kishor, P., Woike, P., & Bindal, J. (2017). Overview on thalassemias: a review article. *Medico Research Chronicles*, *4*(03), 325-337.

Finianos, A., Matar, C. F., & Taher, A. (2018). Hepatocellular carcinoma in β-thalassemia patients: review of the literature with molecular insight into liver carcinogenesis. *International journal of molecular sciences*, *19*(12), 4070.

Adly, A. A., & Ismail, E. A. (2018). Management of Children With β-Thalassemia Intermedia: Overview, Recent Advances, and Treatment Challenges. *Journal of pediatric hematology/oncology*, *40*(4), 253-268.

Li, Y., Ren, Q., Zhou, Y., Li, P., Lin, W., & Yin, X. (2018). Thalidomide has a significant effect in patients with thalassemia intermedia. *Hematology*, *23*(1), 50-54.

Ahmadpanah, M., Asadi, Y., Haghighi, M., Ghasemibasir, H., Khanlarzadeh, E., & Brand, S. (2019). In patients with minor beta-thalassemia, cognitive performance is related to length of education, but not to minor beta-thalassemia or hemoglobin levels. *Iranian Journal of Psychiatry*, *14*(1), 47.

Schmidt, P. J., Liu, K., Visner, G., Fitzgerald, K., Fishman, S., Racie, T., ... & Fleming, M. D. (2018). RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia. *American Journal of Hematology*, *93*(6), 745-750.

Chauhan, W., Shoaib, S., Fatma, R., Zaka-ur-Rab, Z., & Afzal, M. (2022). Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation. *British Journal of Clinical Pharmacology*, *88*(8), 3610-3626.

Bayati, S., Keikhaei, B., Bahadoram, M., Mahmoudian-Sani, M. R., Vaneshani, M., & Behbahani, F. (2021). Radiographic Features of the Maxillofacial Anomalies in Beta-Thalassemia Major: With New View. *World Journal of Plastic Surgery*, *10*(3), 78.

Carsote, M., Vasiliu, C., Trandafir, A. I., Albu, S. E., Dumitrascu, M. C., Popa, A., ... & Sandru, F. (2022). New Entity—Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement. *Diagnostics*, *12*(8), 1921.